The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Prostate Cancer–Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen Era
Open accessAbstract
Purpose: The long-term risk of prostate cancer–specific mortality (PCSM) after radical prostatectomy is poorly defined for patients treated in the era of widespread prostate-specific antigen (PSA) screening. Models that predict the risk of PCSM are needed for patient counseling and clinical trial design. Methods: A multi-institutional cohort of 12,677 patients treated with radical prostatectomy between 1987 and 2005 was analyzed for the risk of PCSM. Patient clinical information and treatment outcome was modeled using Fine and Gray competing risk regression analysis to predict PCSM. Results: Fifteen-year PCSM and all-cause mortality were 12% and 38%, respectively. The estimated PCSM ranged from 5% to 38% for patients in the lowest and highest quartiles of predicted risk of PSA-defined recurrence, based on a popular nomogram. Biopsy Gleason grade, PSA, and year of surgery were associated with PCSM. A nomogram predicting the 15-year risk of PCSM was developed, and the externally validated concordance index was 0.82. Neither preoperative PSA velocity nor body mass index improved the model's accuracy. Only 4% of contemporary patients had a predicted 15-year PCSM of greater than 5%. Conclusion: Few patients will die from prostate cancer within 15 years of radical prostatectomy, despite the presence of adverse clinical features. This favorable prognosis may be related to the effectiveness of radical prostatectomy (with or without secondary therapy) or the low lethality of screen-detected cancers. Given the limited ability to identify contemporary patients at substantially elevated risk of PCSM on the basis of clinical features alone, the need for novel markers specifically associated with the biology of lethal prostate cancer is evident.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696
D'Amico, A. V. (1998) · JAMA · doi:10.1001/jama.280.11.969 · Cited by 4,523
Evaluating the Yield of Medical Tests
Harrell, F. E. (1982) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1982.03320430047030 · Cited by 3,490
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Andriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Gelmann, E. P., Kvale, P. A., Reding, D. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810696 · Cited by 2,906
Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer
Berry, D. A., Cronin, K. A., Plevritis, S. K., Fryback, D. G., Clarke, L., Zelen, M., Mandelblatt, J. S., Yakovlev, A. Y., Habbema, J. D. F., & Feuer, E. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050518 · Cited by 2,460
Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors
Sanda, M. G., Dunn, R. L., Michalski, J., Sandler, H. M., Northouse, L., Hembroff, L., Lin, X., Greenfield, T. K., Litwin, M. S., Saigal, C. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074311 · Cited by 2,253
Self-citationSurrogate endpoints in clinical trials: Definition and operational criteria
Prentice, R. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080407 · Cited by 2,057
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer
Bill-Axelson, A., Holmberg, L., Ruutu, M., Garmo, H., Stark, J. R., Busch, C., Nordling, S., Häggman, M., Andersson, S.-O., Bratell, S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011967 · Cited by 1,900
Freedland, S. J., Humphreys, E. B., Mangold, L. A., Eisenberger, M., Dorey, F. J., Walsh, P. C., & Partin, A. W. (2005) · JAMA · doi:10.1001/jama.294.4.433 · Cited by 1,358
A Preoperative Nomogram for Disease Recurrence Following Radical Prostatectomy for Prostate Cancer
Kattan, M. W., Eastham, J. A., Stapleton, A. M. F., Wheeler, T. M., & Scardino, P. T. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.10.766 · Cited by 1,242
Self-citationMessing, E. M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E. D., & Trump, D. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412401 · Cited by 1,191
20-Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer
Albertsen, P. C. (2005) · JAMA · doi:10.1001/jama.293.17.2095 · Cited by 1,187
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer
Bill-Axelson, A., Holmberg, L., Ruutu, M., Häggman, M., Andersson, S.-O., Bratell, S., Spångberg, A., Busch, C., Nordling, S., Garmo, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043739 · Cited by 1,111
Draisma, G., Boer, R., Otto, S. J., van der Cruijsen, I. W., Damhuis, R. A. M., Schroder, F. H., & de Koning, H. J. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.12.868 · Cited by 1,071
Han, M., Partin, A. W., Pound, C. R., Epstein, J. I., & Walsh, P. C. (2001) · Urologic Clinics of North America · doi:10.1016/s0094-0143(05)70163-4 · Cited by 1,028
Adjuvant Radiotherapy for Pathologically Advanced Prostate Cancer: A Randomized Clinical Trial
Thompson, I. M., Tangen, C. M., Paradelo, J., Lucia, M. S., Miller, G., Troyer, D., Messing, E., Forman, J., Chin, J., Swanson, G., et al. (2006) · JAMA · doi:10.1001/jama.296.19.2329 · Cited by 897
Draisma, G., Etzioni, R., Tsodikov, A., Mariotto, A., Wever, E., Gulati, R., Feuer, E., & de Koning, H. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp001 · Cited by 796
Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy
D'Amico, A. V., Chen, M.-H., Roehl, K. A., & Catalona, W. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032975 · Cited by 740
D'Amico, A. V., Whittington, R., Malkowicz, S. B., Schultz, D., Blank, K., Broderick, G. A., Tomaszewski, J. E., Renshaw, A. A., Kaplan, I., Beard, C. J., et al. (1999) · Journal of Urology · doi:10.1016/s0022-5347(01)61700-2 · Cited by 713
Natural History of Early, Localized Prostate Cancer
Johansson, J.-E. (2004) · JAMA · doi:10.1001/jama.291.22.2713 · Cited by 703
HAN, M., PARTIN, A. W., ZAHURAK, M., PIANTADOSI, S., EPSTEIN, J. I., & WALSH, P. C. (2003) · Journal of Urology · doi:10.1016/s0022-5347(05)63946-8 · Cited by 679
Zincke, H., Oesterling, J. E., Blute, M. L., Bergstralh, E. J., Myers, R. P., & Barrett, D. M. (1994) · Journal of Urology · doi:10.1016/s0022-5347(17)32399-6 · Cited by 672
Stephenson, A. J., Scardino, P. T., Eastham, J. A., Bianco, F. J., Dotan, Z. A., DiBlasio, C. J., Reuther, A., Klein, E. A., & Kattan, M. W. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.867 · Cited by 663
Self-citationHAN, M., PARTIN, A. W., ZAHURAK, M., PIANTADOSI, S., EPSTEIN, J. I., & WALSH, P. C. (2003) · The Journal of Urology · doi:10.1097/00005392-200302000-00018 · Cited by 638
Stephenson, A. J., Scardino, P. T., Eastham, J. A., Bianco, F. J., Dotan, Z. A., Fearn, P. A., & Kattan, M. W. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj190 · Cited by 623
Self-citationBill-Axelson, A., Holmberg, L., Filen, F., Ruutu, M., Garmo, H., Busch, C., Nordling, S., Haggman, M., Andersson, S.-O., Bratell, S., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn255 · Cited by 603
Carter, H. B., Ferrucci, L., Kettermann, A., Landis, P., Wright, E. J., Epstein, J. I., Trock, B. J., & Metter, E. J. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj410 · Cited by 556
Bianco, F. J., Scardino, P. T., & Eastham, J. A. (2005) · Urology · doi:10.1016/j.urology.2005.06.116 · Cited by 553
Self-citationThe Surgical Learning Curve for Prostate Cancer Control After Radical Prostatectomy
Vickers, A. J., Bianco, F. J., Serio, A. M., Eastham, J. A., Schrag, D., Klein, E. A., Reuther, A. M., Kattan, M. W., Pontes, J. E., & Scardino, P. T. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm060 · Cited by 402
Self-citationEffect of Screening and Adjuvant Therapy on Mortality From Breast Cancer
Berry, D. A., Cronin, K. A., Plevritis, S., Fryback, D. G., Clarke, L., Zelen, M., Mandelblatt, J. S., Yakovlev, A. Y., Habbema, J. D. F., & Feuer, E. (2006) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000201966.23445.91 · Cited by 386
Amling, C. L., Riffenburgh, R. H., Sun, L., Moul, J. W., Lance, R. S., Kusuda, L., Sexton, W. J., Soderdahl, D. W., Donahue, T. F., Foley, J. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.132 · Cited by 385
Prostate Cancer and the Will Rogers Phenomenon
Albertsen, P. C., Hanley, J. A., Barrows, G. H., Penson, D. F., Kowalczyk, P. D. H., Sanders, M. M., & Fine, J. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji248 · Cited by 382
Active Surveillance for Prostate Cancer: For Whom?
Klotz, L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3134 · Cited by 353
Freedland, S. J., Humphreys, E. B., Mangold, L. A., Eisenberger, M., Dorey, F. J., Walsh, P. C., & Partin, A. W. (2006) · Journal of Urology · doi:10.1016/s0022-5347(05)00388-5 · Cited by 339
Long-term outcome among men with conservatively treated localised prostate cancer
on behalf of the Transatlantic Prostate Group, Cuzick, J. M., Fisher, G., Kattan, M. W., Berney, D. M., Oliver, R. T. D., Foster, C. S., Møller, H., Reuter, V., Fearn, P., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603411 · Cited by 134
Self-citationImpact of previous local treatment for prostate cancer on subsequent metastatic disease.
Thompson, I. M., Tangen, C. M., Basler, J. W., & Crawford, E. D. (2002) · PubMed · doi:10.1016/s0022-5347(05)64562-4 · Cited by 96
Cited by
Nomograms in oncology: more than meets the eye
Balachandran, V. P., Gonen, M., Smith, J. J., & DeMatteo, R. P. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71116-7 · Cited by 3,292
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D’Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0023 · Cited by 1,532
Self-citationThe Diagnosis and Treatment of Prostate Cancer: A Review
Litwin, M. S., & Tan, H.-J. (2017) · JAMA · doi:10.1001/jama.2017.7248 · Cited by 1,435
Klein, E. A., Cooperberg, M. R., Magi-Galluzzi, C., Simko, J. P., Falzarano, S. M., Maddala, T., Chan, J. M., Li, J., Cowan, J. E., Tsiatis, A. C., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.05.004 · Cited by 659
Self-citation
Metadata
- Authors
- Stephenson, A. J., Kattan, M. W., Eastham, J. A., Bianco, F. J., Yossepowitch, O., Vickers, A. J., Klein, E. A., Wood, D. P., & Scardino, P. T.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-09-10
- Volume
- 27
- Issue
- 26
- Pages
- 4300-4305
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2102229192
- Cited by
- 419
- References
- 37
- FWCI
- 35.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.